STX16

Across TCGA pan-cancer cohorts, STX16 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of STX16’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where STX16 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types STX16 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

CCRCC, PDAC, and LUAD are the cancer types where STX16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STX16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+0.249	<.001	8	view →
PDAC	Male	All	−1.014	.008	4	view →
LUAD	Female	II,III,IV	+0.315	.003	2	view →
HNSC	All	III,IV	−0.304	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

STX16–CCRCC

Open the CCRCC breakdown →